Holen Sie sich die Stockscreener-App
8.229
6.46%
0.499
Handel nachbörslich:
8.27
0.041
+0.50%
Schlusskurs vom Vortag:
$7.73
Offen:
$7.53
24-Stunden-Volumen:
2.84M
Relative Volume:
1.11
Marktkapitalisierung:
$506.46M
Einnahmen:
$3.64M
Nettoeinkommen (Verlust:
$-87.37M
KGV:
-2.0022
EPS:
-4.11
Netto-Cashflow:
$-86.46M
1W Leistung:
+22.09%
1M Leistung:
+68.28%
6M Leistung:
+37.84%
1J Leistung:
+253.18%
1-Tages-Spanne:
$7.51
$8.30
1-Wochen-Bereich:
$6.77
$8.755
52-Wochen-Spanne:
$2.24
$9.10
Verastem Inc Stock (VSTM) Company Profile
Firmenname
Verastem Inc
Sektor
Branche
Telefon
(781) 292-4200
Adresse
117 KENDRICK STREET, NEEDHAM, MA
Vergleichen Sie VSTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
8.229 | 493.59M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Jefferies | Buy |
| 2025-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-31 | Bestätigt | BTIG Research | Buy |
| 2024-09-30 | Eingeleitet | Guggenheim | Buy |
| 2023-11-21 | Fortgesetzt | BTIG Research | Buy |
| 2023-09-27 | Eingeleitet | B. Riley Securities | Buy |
| 2023-06-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-07 | Fortgesetzt | Alliance Global Partners | Buy |
| 2022-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-09 | Eingeleitet | Truist | Buy |
| 2021-07-01 | Eingeleitet | Alliance Global Partners | Buy |
| 2021-05-24 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-06-20 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Eingeleitet | BTIG Research | Buy |
| 2018-05-02 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2015-09-29 | Herabstufung | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2015-09-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Herabstufung | Mizuho | Buy → Neutral |
| 2015-09-28 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-05-12 | Bestätigt | UBS | Buy |
| 2015-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-01-23 | Bestätigt | ROTH Capital | Buy |
| 2014-07-08 | Fortgesetzt | Oppenheimer | Perform |
| 2014-02-11 | Eingeleitet | Mizuho | Buy |
Alle ansehen
Verastem Inc Aktie (VSTM) Neueste Nachrichten
Mizuho Securities Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating - MarketScreener
Breakout Traders Target Verastem Inc. on Recovery SetupWeekly Market Outlook & Precise Swing Trade Entry Alerts - metal.it
Verastem Inc. Earnings Call: Positive Outlook with Key Achievements - MSN
Verastem’s VS-7375 shows efficacy in lung cancer - MSN
Verastem shares rise 8.48% premarket after partner's trial data for GFH375 in lung cancer. - AInvest
Verastem stock rises as BTIG reiterates Buy rating on improved cancer drug data - Investing.com Australia
Verastem Soars 16.58% on Positive NSCLC Trial Data - AInvest
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer - BioSpace
Verastem Unveils Promising VS-7375 Study Results - MSN
Verastem stock soars after KRAS inhibitor shows strong lung cancer results By Investing.com - Investing.com South Africa
Verastem stock soars after KRAS inhibitor shows strong lung cancer results - Investing.com India
Verastem Oncology Announces Late-Breaking Abstract from Partner - GuruFocus
Verastem Oncology Announces Positive Efficacy Data for Partner GenFleet Therapeutics' KRAS G12D Inhibitor VS-7375 in Advanced Non-Small Cell Lung Cancer. - AInvest
Verastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Call Transcript - Insider Monkey
Can Verastem Inc. stock double in the next yearReturn-Focused Stock Plans - thegnnews.com
Will Verastem’s Stock Keep Rising? - StocksToTrade
Verastem (VSTM.O) Surges 19.9% on KDJ Golden Cross and Mysterious Order Flow - AInvest
Verastem Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Verastem Seeks to Raise $300M through Mixed Securities Shelf - AInvest
Verastem's New Ovarian Cancer Drug Sees Strong Sales, Analysts Predict Significant Upside - AInvest
Verastem (VSTM.O) Surges 19.9%: What’s Behind the Sharp Intraday Move? - AInvest
Verastem's Q2 Earnings Exceed Expectations on Strong Ovarian Cancer Drug Sales - AInvest
Using Python tools to backtest Verastem Inc. strategiesAI Trend Detection for Entry Timing - Newser
What makes Verastem Inc. stock price move sharplyMassive ROI Stock Selections - thegnnews.com
Verastem's (VSTM) Breakthrough in KRAS-Driven Cancers and Commercialization Momentum - AInvest
Transcript : Verastem, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Verastem stock climbs on Q2 beat (VSTM:NASDAQ) - Seeking Alpha
Verastem’s Promising Phase 3 Study in Ovarian Cancer: A Potential Game-Changer? - TipRanks
RBC Raises Price Target on Verastem to $13 From $12, Keeps Outperform, Speculative Risk - MarketScreener
Verastem Inc files for mixed shelf offering of up to $300 millionSEC filing - MarketScreener
Earnings call transcript: Verastem Q2 2025 sees revenue growth and FDA approval - Investing.com
Verastem’s Promising Market Expansion and Financial Health Drive Buy Rating - TipRanks
Verastem: Q2 Earnings Snapshot - Connecticut Post
Verastem Q2 2025 Earnings Call Transcript - MarketBeat
Verastem Inc (VSTM) Q2 2025 Earnings Call Highlights: FDA Approval and Strong Launch Drive ... By GuruFocus - Investing.com Canada
Verastem Oncology’s Q2 2025 Financial and Business Highlights - TipRanks
Verastem Inc (VSTM) Q2 2025 Earnings Call Highlights: FDA Approval and Strong Launch Drive Positive Momentum - GuruFocus
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - BioSpace
Verastem 2025 Q2 Earnings Deepened Losses Amid Product Launch - AInvest
Verastem Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Custom strategy builders for tracking Verastem Inc.Free Short Term Buy List With Stop Protection - Newser
Verastem Oncology Gambles On Cancer Drug Launch Despite Deepening Losses - Finimize
Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Verastem's Q2 2025 Earnings and Pipeline Progress: A Deep Dive into R&D Momentum and Long-Term Value Creation - AInvest
Biopharma firm Verastem Oncology Q2 net loss widens - MarketScreener
Verastem reports Q2 EPS (39c) vs. (31c) last year - TipRanks
Verastem CEO Paterson sells $7,738 in shares By Investing.com - Investing.com South Africa
Verastem CEO Paterson sells $7,738 in shares - Investing.com
Will Verastem Inc. continue its uptrendIntelligent Trade Forecast With AI Analytics - Newser
Intrinsic Value of Verastem Inc. Stock: Is It Undervalued or OvervaluedTechnical Trend Forecast for Investors - Newser
Best data tools to analyze Verastem Inc. stockTrading Watchlist with Real Time Filters - Newser
Finanzdaten der Verastem Inc-Aktie (VSTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):